Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 10/20 | 0.70 |
| ▸ | MTNR1A | P48039 | 9/20 | 0.70 |
| ▸ | CCR2 | P41597 | 1/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.45 |
| ▸ | EDNRB | P24530 | 1/20 | 0.44 |
| ▸ | EDNRA | P25101 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6778354 | 0.82 | MTNR1B (0.66) | MTNR1BMTNR1ACCR2MAPTPLA2G2A | |
| SCHEMBL26473 | 0.80 | MTNR1B (0.67) | MTNR1BMTNR1ACCR2MAPTPLA2G2A | |
| SCHEMBL6775247 | 0.79 | CCR2 (0.65) | MTNR1BMTNR1ACCR2MAPTPLA2G2A | |
| SCHEMBL25136 | 0.79 | MTNR1B (0.60) | MTNR1BMTNR1ACCR2MAPTKDM4E | |
| SCHEMBL13632218 | 0.77 | MTNR1B (0.60) | MTNR1BMTNR1ACCR2MAPTPLA2G2A | |
| SCHEMBL13632216 | 0.76 | MTNR1A (0.54) | MTNR1BMTNR1AMAPTKDM4EPLA2G2A | |
| SCHEMBL2157047 | 0.75 | MAPK1 (0.58) | MTNR1BMTNR1ACCR2MAPTPLA2G2A | |
| SCHEMBL26613 | 0.74 | PLA2G2A (0.59) | MTNR1BMTNR1ACCR2MAPTKDM4E | |
| SCHEMBL6774080 | 0.73 | MTNR1A (0.56) | MTNR1BMTNR1ACCR2MAPTPLA2G2A | |
| SCHEMBL3199215 | 0.72 | MTNR1A (0.45) | MTNR1BMTNR1ACCR2MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713645-B1 | INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK | ELI LILLY AND COMPANY | 2004-03-30 | — | — | US | disclosed |
| EP-0950661-B1 | Substituted tricyclics useful in sPLA2 induced diseases | LILLY CO ELI (US) | 2003-11-12 | — | — | EP | disclosed |
| EP-1156050-A2 | Substituted tricyclics useful in sPLA2 induced diseases | ELI LILLY AND COMPANY (US) | 2001-11-21 | — | — | EP | disclosed |
| US-6177440-B1 | THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR | ELI LILLY AND COMPANY | 2001-01-23 | — | — | US | disclosed |
| EP-0950661-A1 | Substituted tricyclics useful in sPLA2 induced diseases | ELI LILLY AND COMPANY (US) | 1999-10-20 | — | — | EP | disclosed |